OLEMA PHARMACEUTICALS, INC. Long-term Line of Credit, Noncurrent
OLEMA PHARMACEUTICALS, INC. (OLMA) had Long-term Line of Credit, Noncurrent of $3.00 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermLineOfCredit · last filed 2026-08-10
- 2026-06-30: Long-term Line of Credit, Noncurrent $3.00M.
- 2026-03-31: Long-term Line of Credit, Noncurrent $3.00M.
- 2025-12-31: Long-term Line of Credit, Noncurrent $3.00M.
- 2025-09-30: Long-term Line of Credit, Noncurrent $3.00M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2026-06-30 | $3.00M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $3.00M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $3.00M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.00M 10-Q · filed 2025-08-11 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |